Skip to main content
ScholarsBetaWeill Cornell Medicine

Overview

In our lab, there is broad range in expertise and research emphasis across themes of somatic evolution and human genomics, encompassing both experimental and computational labs. Our strength derives from the unique makeup of our group, with each individual bringing their passion and intellect to tackle the most fascinating and challenging questions in human somatic evolution, disease genomics, cancer evolution, single-cell biology, cell-free DNA technology and beyond.

Highlights

  1. 1
    Nature biotechnology · 2023
    NBNir Ben ChetritDADan Avi Landau
    PMID: 36593397PMCID: PMC10272089DOISenior author178 citations
  2. 2
    Nature genetics · 2020
    ANAnna NamRLRoss L. LevineOAOmar Abdel-wahabDADan Avi Landau
    PMID: 32203468PMCID: PMC7216752DOISenior author193 citations
  3. 3
    Nature genetics · 2021
    AAAlicia AlonsoDADan Avi Landau
    PMID: 34594037PMCID: PMC8675181DOISenior author208 citations

Publications

120 publications

Funding

64 grantsView NIH portfolio on RePORTER ↗

Active

24 grants
  • Co-I
    The role of MGA in the pathogenesis of Richter Transformation
    National Cancer Institute · 2026–2031
    R37CA304192-01A1
  • Sub-PI
    Defining the determinants of long term CAR-T persistence
    National Cancer Institute · 2026–2031 · via University of Pennsylvania
    R01CA300058-01A1
  • Sub-PI
    Delineation of Proteotoxic stress and Bone Marrow Failure in VEXAS Syndrome
    National Heart, Lung, and Blood Institute · 2025–2030 · via New York University School of Medicine (Grossman)
    R01HL175155-02
  • Sub-PI
    Center for Integrated Cellular Analysis
    National Human Genome Research Institute · 2020–2029 · via New York Genome Center Inc.· 2 renewals
    RM1HG011014-07
  • PI
    Harnessing ecDNA and aneuploidy signals in plasma whole genome for early detection of ovarian cancer
    Ovarian Cancer Research Alliance · 2026–2028
    CRDG-2026-3-2354
  • Sub-PI
    Circulating cell free tumor DNA (ctDNA) as a biomarker of cancer progression in patients with immune checkpoint inhibitor associated arthritis treated with immunosuppressive medications
    National Inst of Arthritis & Musculoskeletal & Skin Diseases · 2025–2028 · via Hospital for Special Surgery
    R01AR085258-01A1
  • PI
    Precision single-cell mapping of chromatin-associated protein activity by molecular footprinting to chart disruptions to gene regulation and dissect tumor heterogeneity in cancer
    National Cancer Institute · 2025–2028
    R33CA302607-02
  • Co-I
    Characterizing stem cell-like B cell subpopulations and dissecting their role in tumorigenesis
    National Cancer Institute · 2023–2028
    R01CA283327-01
  • PI
    Single-cell multi-omics to link clonal mosaicism (CM) genotypes with chromatin, epigenomic, transcriptomic and protein phenotypes
    National Institute of Neurological Disorders and Stroke · 2023–2028
    UH3NS132139-04
  • PI
    Solving the early detection challenge in ovarian cancer through transformative liquid biopsy innovations
    The Mark Foundation for Cancer Research · 2026–2027
    MFCR 253967-01
  • Sub-PI
    Advancing the therapeutic landscape for Chronic Myelomonocytic Leukemia (CMML)
    Leukemia & Lymphoma Society · 2023–2027 · via H. Lee Moffitt Cancer Center & Research Institute
    MCCRI 69-22751-01-01-G4
  • Co-I
    Targeting Unmet Needs For B-cell Lymphomas
    Leukemia & Lymphoma Society · 2022–2027
    LLS 7027-23
  • Co-I
    The Immune Niche in the Development of Hematological Malignancies and Implications for Novel Therapy (Core 2: Spatial, Single-cell, and Integrative Informatics and Statistics Core)
    Leukemia & Lymphoma Society · 2022–2027 · via University Health Network
    LLS 7029-22
  • Sub-PI
    Maximizing Detection of Childhood Brain Tumors in Biofluids
    Brain Tumor Funders' Collaborative · 2025–2027 · via St. Jude Children's Research Hospital
    SJCRH 254897-01
  • PI
    Defining Mechanisms of Resistance to Therapy in BTK-mutant Chronic Lymphocytic Leukemia
    CLL Global Research Foundation · 2026–2027
    CLLGR 260233-01
  • PI
    Genome-wide mutational integration for ultra-sensitive plasma tumor burden monitoring in immunotherapy
    National Cancer Institute · 2022–2027
    R01CA266619-05
  • PI
    Deciphering the fitness determinants of clonal mosaicism- ELA Stage II
    The Mark Foundation for Cancer Research · 2025–2026
    TMFCR 21-042-ELA Stage II
  • PI
    Harnessing Innate Immunity for Next-Generation Immuno-Oncology Therapeutics
    American Cancer Society · 2024–2026
    YACS-24-1331829-01-YACS
  • PI
    BWF 2015 Career Award for Medical Scientists
    Burroughs Wellcome Fund · 2015–2026
    BWF 1014689.01 19-20
  • PI
    Precision, plasma-only, melanoma ctDNA residual disease monitoring
    Melanoma Research Alliance · 2023–2026
    MRA 227409-03
  • PI
    Defining the role of DNA methylation modifier mutations in reshaping blood differentiation topology
    Leukemia & Lymphoma Society · 2021–2026
    LSS 1373-21
  • Sub-PI
    Deciphering heritability, plasticity and differentiation trajectories in gliomas via single-cell multi-omics
    National Cancer Institute · 2021–2026 · via The General Hospital Corporation (dba Massachusetts General Hospital)
    R01CA258763-05
  • MPI
    Charting the differentiation topology of SF3B1 mutated clonal hematopoiesis (CH) and myelodysplastic syndromes (MDS) via a multi-omics single-cell toolkit
    National Heart, Lung, and Blood Institute · 2022–2026
    R01HL157387-04
  • PI
    RCA with Montage Bio, Inc.
    Montage Bio, Inc. · 2024–2025BioPharma Alliance
    BP 243333-01
Completed grants (40)
  • PI
    Uncovering Novel Regulators of HSC Fate Control
    Tri-Institutional Stem Cell Initiative (Weill Cornell) · 2023–2025
    Tri-Sci #2023-009
  • Sub-PI
    Developing Novel Therapeutic Approaches for Classical and Variant Hairy Cell Leukemia (Project 1)
    Leukemia & Lymphoma Society · 2021–2025 · via Memorial Sloan Kettering Cancer Center
    HCL8028-22
  • Sub-PI
    Developing Novel Therapeutic Approaches for Classical and Variant Hairy Cell Leukemia (Core 2)
    Leukemia & Lymphoma Society · 2021–2025 · via Memorial Sloan Kettering Cancer Center
    HCL8028-22
  • PI
    Expanding the GoT toolkit to link single-cell clonal genotypes with protein, transcriptomic, epigenomic and spatial phenotypes
    National Cancer Institute · 2022–2025
    R33CA267219-03
  • PI
    Torrey Coast Foundation Macrophage Proposal
    Torrey Coast Foundation · 2024–2025
    TCF 243106-01
  • Sub-PI
    Mosaic: post-zygotic mutations in vascular and lymphatic developmental disorders.
    National Heart, Lung, and Blood Institute · 2020–2025 · via Seattle Children's Hospital
    R01HL130996-09
  • PI
    Deciphering the fitness determinants of clonal mosaicism
    The Mark Foundation for Cancer Research · 2022–2024
    TMFCR 21-042-ELA
  • Sub-PI
    Genetic Reprogramming of the Solid Tumor Immune Microenvironment
    Emerson Collective Cancer Research Fund · 2021–2024 · via University of Pennsylvania
    UP 215255-02
  • PI
    Deciphering differentiation hierarchies, heritability and plasticity in gliomas via single-cell multi-omics.
    Sontag Foundation, Inc. · 2020–2024
    SFI 203261-04
  • PI
    Addgene 796255
    Addgene, Inc. · 2023–2024Contract
    Addgene 796255
  • PI
    A multi-omics, single-cell toolkit to study disrupted hematopoietic differentiation in clonal hematopoiesis
    The Vallee Foundation INC · 2020–2024
    Vallee Foundation 203110-04
  • Sub-PI
    Experimental And Preclinical Modeling Of NUP98-Rearranged Acute Leukemia
    National Cancer Institute · 2020–2024 · via St. Jude Children's Research Hospital
    U54CA243124-01S1
  • PI
    Defining Epidrivers of CLL Evolution in Response to Targeted Therapy
    National Cancer Institute · 2018–2024
    R01CA229902-05
  • KP
    Multi-Omic and Cellular Trajectories of Clonal Hematopoiesis in Acute Myeloid Leukemia
    Daiichi Sankyo Co., Ltd. · 2021–2024BioPharma Alliance
    BP 214628-01
  • PI
    Defining the evolutionary mechanisms of IDH-mutant glioma progression through single-cell multi-omics innovation
    Starr Cancer Consortium · 2022–2023
    I15-0028
  • Sub-PI
    Mechanisms of enhancer regulation in leukemia
    National Cancer Institute · 2019–2023 · via New York University Medical Center
    R01CA228135-05
  • PI
    Shapeshifters in Cancer: Defining the Fundamental Forces of Leukemia Evolution
    National Cancer Institute · 2018–2023
    DP2CA239065-01
  • PI
    The role of DNA methylation modifiers in shaping the hematopoietic differentiation topology
    National Heart, Lung, and Blood Institute · 2019–2023
    R01HL145283-04
  • PI
    Understanding and characterizing the role of splicing factor mutations in progression of myeloproliferative neoplasms to accelerated and blast phase
    Tri-Institutional Stem Cell Initiative (Weill Cornell) · 2021–2023
    Tri-Sci #2021-004
  • PI
    Deciphering cellular hierarchies and plasticity in diffuse gliomas by single-cell multi-omics (Competitive Renewal)
    William Rhodes Center for Glioblastoma - Collaborative Research Initiative · 2020–2022
    NYPH 203205-02
  • Sub-PI
    Genome of Transcriptome (GoT) to study CHIP Inflammation in Atherosclerosis
    Chan Zuckerberg Initiative · 2021–2022 · via New York University School of Medicine (Grossman)
    NYUSM 2-A0-00-1007627,
  • PI
    Uncovering HSC fate decisions with single-cell profiling
    Tri-Institutional Stem Cell Initiative (Weill Cornell) · 2020–2022
    2019-016
  • Sub-PI
    Genome of Transcriptome (GoT) to study CHIP Inflammation in Atherosclerosis
    Chan Zuckerberg Initiative · 2020–2021 · via Mount Sinai School of Medicine
    MSSM 2020-218415
  • PI
    Ultra-Sensitive cfDNA detection for high-risk colorectal adenomas
    The Mark Foundation for Cancer Research · 2020–2021
    MFCR 201907-01
  • PI
    Shapeshifters in Cancers – Defining Epidrivers of Cancer Evolution in Response to Targeted Therapy
    Pershing Square Sohn Cancer Research Alliance · 2018–2021
    No publications yet
    PSSCR 194743-01
  • KP
    Investigating Wnt/beta-catenin dependent tumor-microenvironment interactions that contribute to metastasis in Ewing sarcoma
    National Cancer Institute · 2019–2021Career
    K00CA234810-02
  • Co-I
    Delineating Sperm Heterogeneity with Single-Cell Omics (Alliance with Ohana)
    Ohana Biosciences · 2020–2021BioPharma Alliance
    OB 204314-01
  • KP
    Non-genetic determinants of the cancer clonal evolution
    Institut Curie · 2018–2020
    IC 190654-01
  • PI
    Ultra-sensitive detection of cancer circulating tumor DNA through genome wide integrated signals
    Daedalus Fund for Innovation (Weill Cornell) · 2018–2020
    DFI 200275-01
  • PI
    Cupid-seq – high throughput transcriptomic spatial mapping of immune-tumor interactions in the micro-environment
    American Association for Cancer Research · 2018–2020
    SU2C-AACR-PS-20
  • Sub-PI
    Ultra-sensitive detection of circulating tumor DNA
    American Lung Association, Incorporated · 2018–2020 · via New York Genome Center Inc.
    No publications yet
    NYGCI 182361-01
  • PI
    Algorithmically-Driven Personalized Combination Therapy for CLL
    Leukemia & Lymphoma Society · 2016–2020
    LLS 6523-17
  • PI
    Ultra-sensitive Detection of Circulating Tumor DNA Through Genome-Wide Integration for Early Detection and Dynamic Cancer Monitoring to Transform Cancer Care and Outcomes
    The Mark Foundation for Cancer Research · 2018–2019
    2018-Q4-ASP-001
  • PI
    Algorithmically-Driven Quantitative Combination Cancer Therapy Engineering
    American Association for Cancer Research · 2016–2019
    SU2C-AACR-IRG-06-16
  • PI
    ASH Scholar Award for Junior Faculty
    American Society of Hematology Inc · 2017–2019
    ASH 184392-02
  • PI
    The Role of Epigenetic Heterogeneity in CLL Evolution
    National Institute of Environmental Health Sciences · 2016–2019Career· 2 renewals
    K01ES025431-03
  • PI
    Discovery of Epigenetic Drivers of Tumor Evolution
    Starr Cancer Consortium · 2017–2018
    SCC 17070945-02
  • PI
    Algorithmically-Driven Quantitative Combination Leukemia Therapy
    Sidney Kimmel Cancer Center Foundation · 2016–2018
    No publications yet
    SKCCF 170894-02
  • Sub-PI
    Deciphering the Mechanisms Underlying Differential Disease Phenotypes of JAK2 V617F in Myeloproliferative Neoplasms
    National Cancer Institute · 2017–2018 · via Columbia University
    U54CA193313-03
  • PI
    Development of a New Class of Novel Immunotherpaeutic Drug Candidates That Overcome NK Suppression by TAMS by Harnessing the Innate Immune System Through the Use of a Novel Scalable Phenotypic...
    Daedalus Fund for Innovation (Weill Cornell) · 2017–2018
    DFI WC 17091492-01

Honors & distinctions

2 honors
  • Member · American Society for Clinical Investigation · 2020
  • Career Award · Burroughs Wellcome Fund · 2015

Clinical research

1 study
Completed & closed trials (1)
  • PI
    Charting the differentiation topology of SF3B1 mutated clonal hematopoiesis (CH) and myelodysplastic syndromes (MDS) via a multi-omics single-cell toolkit
    Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2026)

Available technologies

6 technologiesView full WCM portfolio ↗
Show 1 more technology

News mentions

28 mentionsView all WCM news ↗
Show 23 more mentions

Media highlights

5 clips

Mentoring

22 menteesAll publications with mentees →
2 MD students · 6 PhD students · 2 MD-PhD students · 12 Postdocs

External relationships

Ownership

1DER INC · BioSkryb Genomics INC · Circadian OS · ImmunAI INC · Montage Bio, Inc · Ultima Genomics, Inc. · Veracyte, Inc.

Advisory/Scientific Board Member

1DER INC · BioSkryb Genomics INC · Circadian OS · ImmunAI INC

Proprietary Interest

Montage Bio, Inc · Veracyte, Inc.

Other

Ultima Genomics, Inc. · Veracyte, Inc.